Premier Inc. and 11 Leading Health Systems Invest in Exela Pharma Sciences to Secure and Support U.S.- Based Drug Supply and Manufacturing
Summary
COVID-19 has exacerbated pharmaceutical sourcing challenges as overseas manufacturing, export bans from large producers of APIs and demand spikes have, at times, left providers struggling to secure basic, life-saving therapies for patients. “With this investment, we are committing to support the domestic production of vital medicines for our members and the market ─ and to bring much-needed solutions to help eliminate drug shortages.” “Both Exela’s commitment to, and track record of, addressing drug shortages as well as its experience in supplying 503B compounded products make them an ideal partner for Premier and our members,” added Andy Brailo, Chief Customer Officer at Premier. The collaboration with Exela builds on this legacy and represents another step forward in Premier’s long-term resiliency strategy – working with members to pursue innovative relationships with U.S. companies that specialize in critical product categories. Exela Pharma Sciences, LLC is a fast-growing US based integrated specialty pharmaceutical company, that develops, manufactures and markets proprietary and generic sterile injectable products with the healthcare provider and patient in mind. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide.